NRx Pharmaceuticals, Inc. Stock News

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Matthew Duffy - Company's Chief Business Officer Stephen Willard - Chief Executive

2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional invest

2024 Catalysts: Positive Clinical Data, Two Planned NDAs, Company Launch of Hope Therapeutics; FDA QIDP award in cUTI and New Schizophrenia Opportunity Executed Term Sheet from an institutional invest

RADNOR, Pa. , May 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will par

RADNOR, Pa. , May 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will rele

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that was sustained over 42 days (Effect Size

NRX-101 is first oral antidepressant to show 33% advantage in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relativ

The latest trading day saw NRx Pharmaceuticals, Inc. (NRXP) settling at $3.14, representing a +0.64% change from its previous close.

In the most recent trading session, NRx Pharmaceuticals, Inc. (NRXP) closed at $3.04, indicating a +0.66% shift from the previous trading day.

NRX Pharmaceuticals (NASDAQ: NRXP ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a proposed public offering for its shares. NRX Pharmaceuticals is selling

The Nasdaq Panel has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter Four upcoming milestones expected: data from trials in Suicida

RADNOR, Pa. , April 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced the pricing

RADNOR, Pa. , April 17, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)("NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it inte

Formulation based on prior patents by NRx founder Achieved pH neutral formulation of ketamine, potentially enabling both intravenous (IV) and subcutaneous (SQ) administration Company expects Compositi

Data transferred for independent statistical analysis Top-line data expected in April 2024 RADNOR, Pa. , April 8, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals",